News - Immunologicals, Biotechnology


Popular Filters

1 to 25 of 59 results

Beike receives approval from Chinese FDA for umbilical stem cells in lupus

Beike receives approval from Chinese FDA for umbilical stem cells in lupus


China-based stem cell research company Beike Biotechnology has been accepted into the approval process…

beikeBeike BiotechnologyBiotechnologyChinaGuangdong Food and Drug AdministrationImmunologicalsRegulationStem cells

MorphoSys and Merck Serono collaborate on immuno-oncology

MorphoSys and Merck Serono collaborate on immuno-oncology


German companies MorphoSys and Merck KGaA unit Merck Serono today announced the signing of an agreement…

BiotechnologyCancer therapyHealth Medical PharmaHuman antibody technologiesImmune systemImmunologicalsLeaderLicensingMerck KGaAMerck SeronoMorphoSysOncologyResearch

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders


US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

MacroGenics and Takeda link up to develop DART for autoimmune disorders


Privately held US biotech firm MacroGenics and Japan’s largest drugmaker Takeda Pharmaceutical have…

BiotechnologyImmunologicalsLicensingMacroGenicsMGD010Takeda Pharmaceutical

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility


Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

FDA extends PDUFA date for Baxter and Halozyme’s HyQvia


US drugmakers Baxter International and Halozyme Therapeutics revealed that the US Food and Drug Administration…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Timing of AstraZeneca’s positive pipeline announcement “pertinent” in wake of takeover battle with Pfizer, say GlobalData analysts


Anglo-Swedish drug major AstraZeneca may have more ammunition to deliver on promises made to investors…


AnaptysBio and Tesaro team up in $340 million oncology deal


Therapeutic antibody discoverer AnaptysBio announced a strategic immuno-oncology collaboration with fellow…


Abide Therapeutics in deal with Celgene on immune disorders research


Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Pediatric indication for SOBI’s Kineret from UK’s MHRA

Pediatric indication for SOBI’s Kineret from UK’s MHRA


Kineret (anakinra), from Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI), has been licensed…


Lophius Biosciences Appoints Dr Robert Phelps as director of business operations


German biotechnology company Lophius Biosciences GmbH has announced that Dr Robert Phelps has joined…

Antibiotics and Infectious diseasesBiotechnologyBoardroomEuropeImmunologicals

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL


Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

New cancer immunotherapeutics firm Agalimmune set up


Agalimmune, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for…


Roche and immatics ink mega-million cancer vaccine and immunotherapy deal

Roche and immatics ink mega-million cancer vaccine and immunotherapy deal


Germany’s privately-held immatics biotechnologies GmbH and Swiss drug major Roche have entered into…

BiotechnologyIMA942immatics biotechnologiesImmunologicalsOncologyRocheVaccines

Rigel sees clear forward path for fostamatinib but will drop R333


Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

Gliknik enters licensing agreement with Pfizer


Gliknik has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, which is…

BiotechnologyGliknikImmunologicalsLicensingNorth AmericaOncologyPfizer

Ablynx and Merck Serono expand collaboration on Nanobodies

Ablynx and Merck Serono expand collaboration on Nanobodies


Ablynx and Merck Serono have expanded their collaboration on the co-discovery and co-development of Nanobodies.

AblynxBiotechnologyEuropeImmunologicalsMerck SeronoNeurologicalOncologyResearch

Novartis links with Regenerex in cell therapy research collaboration


Swiss drug major Novartis (NOVN: VX) has entered into an exclusive global licensing and research collaboration…


US firms establish strategic partnership around biosimilars


Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Novartis enters into a collaboration for Il-17 inhibitor


US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research


Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Merck Serono sets up new platform for cancer therapies innovation


Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData


Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Additional indications in Japan for Roche's Avastin and Astellas' Prograf


Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

1 to 25 of 59 results

Back to top